Data Sheet (Cat.No.T39262L)

TargetMol

BIM-23190 aceate

Chemical Properties



CAS No. :

Formula: C59H83N13O14S2

Molecular Weight: 1262.5

Storage: Keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	BIM-23190 aceate, a somatostatin analog, a selective agonist of SSTR2 and SSTR5. BIM-23190 can be used in cancer and acromegaly studies.
Targets(IC50)	Somatostatin
In vitro	BIM-23190 tends to mildly stimulate PRL secretion. The Ki values are 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively[3].
In vivo	In male athymic nude (nu/nu) mice, BIM-23190 (50 μg/mouse, twice a day) significantly reduced the tumor growth rate and exhibited significant anti-tumor (C6 glioma) activity [1].

Solubility Information

Solubility	DMSO: 12.63 mg/mL (10 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.7921 mL	3.9604 mL	7.9208 mL
5 mM	0.1584 mL	0.7921 mL	1.5842 mL
10 mM	0.0792 mL	0.396 mL	0.7921 mL
50 mM	0.0158 mL	0.0792 mL	0.1584 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Federica Barbieri, et al. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1078-88.

T J Gillespie, et al. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. J Pharmacol Exp Ther. 1998 Apr;285(1):95-104.

I Shimon, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest. 1997 Nov 1;100(9):2386-92.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481